Cadrenal Therapeutics Announces Positive FDA Type D Meeting for CAD-1005

What Happened

• Cadrenal Therapeutics, Inc. (CVKD) filed an 8-K on August 31, 2026 reporting positive feedback from a Type D meeting with the U.S. Food and Drug Administration held July 28, 2026. The company and the FDA aligned on key elements of the protocol and Statistical Analysis Plan for a Phase 3 registrational trial of CAD-1005, a first‑in‑class 12‑lipoxygenase (12‑LOX) inhibitor in development to treat heparin‑induced thrombocytopenia (HIT).
• The FDA agreed to an optimized primary endpoint definition focused on “worsening HIT” measured by progression of thrombotic events through Day 14 of treatment or hospital discharge, and to include extension of an existing thrombus into a new vascular segment/bed to reduce site‑to‑site variability. The primary endpoint will assess the proportion of Serotonin Release Assay‑positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events through Day 14 or discharge. The FDA also accepted a placebo‑controlled design with standard anticoagulation therapy provided in both arms. A related press release was furnished as Exhibit 99.1.

Key Details

• Type D meeting date: July 28, 2026; 8‑K and press release filed August 31, 2026.
• Primary endpoint: proportion of SRA+ participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
• Worsening HIT definition includes thrombus extension into a new vascular segment/bed (to avoid manual size‑measurement variability).
• FDA agreed to a placebo‑controlled Phase 3 with existing standard anticoagulation in both CAD‑1005 and placebo arms.

Why It Matters

• Alignment with the FDA on endpoint definitions and trial design reduces regulatory uncertainty and clarifies the path for a registrational Phase 3 trial of CAD‑1005, which is a material development milestone for the company.
• Agreement on a clear, adjudicated primary endpoint and use of placebo control (with standard anticoagulation in both arms) should improve consistency of data across sites and help define the trial’s statistical analysis plan and operational requirements—factors that can affect trial size, timing and costs.
• For investors, these developments represent de‑risking of the clinical program by addressing key regulatory and endpoint questions that are central to a successful registrational study.